Log in
Cognitive Stimulation Therapy (CST) is an evidence-based, brief, group therapy for people with mild to moderate dementia. It was developed and evaluated by UCL in collaboration with Bangor University. Our research showed significant benefits in cognition and quality of life plus cost-effectiveness. Cognitive Stimulation for people with mild/moderate dementia of all types is recommended by NICE and is now in widespread use across the UK and the rest of the world in a variety of settings including care homes, hospitals and the community. A recent audit by the Memory Services National Accreditation Programme reported that 66% of UK memory clinics surveyed were using CST.
Childhood obesity is an increasing problem in the UK with roughly one in seven school aged children in Scotland and England being classified as obese. The picture is similar in Wales where the prevalence is one in eight. The direct cost of obesity to the NHS is estimated to be £4.2bn a year, with this set to rise if the causes of childhood obesity are not addressed. The contribution of the research described below to tackling this issue is manifold: it has enabled the development and improvement of child health interventions/programmes; it has allowed commissioners and programme leads to make more informed decisions about investment in these interventions/programmes; and it has contributed to the development of regional healthy weight strategies and national guidelines on weight management.
Psychosis is a serious mental illness for which treatment can be aided by psychological therapies. Researchers at King's College London (KCL) demonstrated that family environment is key to recovery and developed and validated a family intervention for psychosis. Family intervention for psychosis is a recommended treatment in NICE guidelines (2009), as well as by the Patient Outcomes Research Team in the USA. The NICE guideline committee was chaired and advised by KCL researchers. Family intervention for psychosis is part of training programs for clinical staff and has changed NHS practice. The KCL-led website mentalhealthcare.org.uk disseminates this research to families of those with psychosis.
This case study is built upon the successful fusion of Spatial Planning with the Ecosystem Approach, translating complex theory into operational outputs for public and stakeholder engagement, which improve policy processes and outcomes across built and natural environments and fringe interfaces. `RUFopoly' and `EATME tree' are co-produced outputs, maximising engagement in learning spaces within game and web-portal formats respectively. For example, the Welsh Government has used both tools to design emerging policy frameworks (testimonial1). The novel research model employed builds research teams that integrate academic, policy and practice participants within a collective journey of (re)-discovery maximising reflective practice and social learning.
Lancaster research has changed the understanding and treatment of bipolar disorder (BD) from biological models and pharmacological treatments to integrated psychosocial interventions complementary to routine medication and matched to user needs. We have developed novel psychological interventions (individual, family and group approaches), and reliable and valid ways to assess valued outcomes and underlying mechanisms of change. This research has delivered 3 major impacts. It has: fundamentally changed understanding of the condition in professional and lay audiences; changed treatment in terms of policy and practice, including NICE clinical guidelines; changed professional training delivered both nationally and internationally.
The Centre For Community Mental Health (CCMH) is a research team within the Centre for Health and Social Care (CHSCR). CCMH develops and supports research that reduces stigma and social exclusion and which empowers people with mental health problems to lead fulfilling lives in their own communities. The impact of this research has challenged prevailing beliefs and practices and led directly to changes in practice, organisational processes and service design across the world.
Our studies of voice hearing, in adults and children, have shown that it may not always be associated with mental illness and that cognitive behavioural therapy is effective for many people. Our work has led to the development of the Hearing Voices Movement and the International Hearing Voices Network, which now spans 22 countries and which enables people who hear voices to find bespoke solutions and lead normal lives.
The impact of our work on community-based approaches to the management of acute and long term mental ill health led, first, to the development of assertive outreach and crisis resolution teams that reduced hospital admissions by treating people at home; second, our work has led directly to service redesign in many different countries.
Our studies of special and underserved social groups in relation to mental ill health have demonstrated the multiple barriers to services that many people experience. The impact of these studies has included changes in organisational practices to promote greater engagement with service users.
Long term conditions are leading causes of death and disability. Over 80% of care for people with long term conditions is self-management. In 2001, the Chief Medical Officer concluded, from evidence from the US and from Barlow and Turner's pioneering research in the UK, that the NHS should provide support for self-management through programmes such as the Expert Patient Programme. Turner and McHattie have developed self-management programmes (e.g. the Help to Overcome Problems Effectively: HOPE Programme) which have been taken up by local, national and international providers. These programmes have impacted positively on patient-reported outcome measures such as pain, fatigue and depression. They are cost-effective and produce a social return on investment.
The project:
Alzheimer's disease (AD) affects one in seven of the population over 60 years of age, and represents an increasing burden on worldwide medical and care resources. Treatments currently available are symptomatic. Despite pharmaceutical industry efforts there has been little indication of a marketable product for long-term treatment.
To address this problem, a joint venture was established in 2001 between the University of Aberdeen and TauRx Pharmaceuticals. A team was created of chemists, biologists, animal behaviourists, working together with a clinical trial team. A drug effective against the progress of AD based on the compound methylene blue was synthesised and scaled up within the Chemistry Department (led by Professor John Storey), with a quality that was proved acceptable through successful phase two clinical trials (2006-8), and is now used in phase three clinical trials which are due to complete in 2015. Several other drug candidates have also been developed and evaluated in pre-clinical and phase one clinical studies that show promise. Collaborations with commercial pharmaceutical companies have as a result led to the manufacture of significant quantities of drug medicines for TauRx Pharmaceuticals based on IP generated within the Chemistry Department and these drugs have been used in clinical trials and for named patient supply (c. 60 patients). This has resulted in increased commercial revenue for these companies and the creation of new employment.
Aston's research on inward investment has had considerable reach and significance, improving economic policy analysis on the effects of foreign direct investment (FDI). The research has: